23 - 24 June 2021
10th Annual Biologics Manufacturing Korea 2021
Virtual
Don't Miss Out On Biologics Manufacturing Korea 2021
500+
Expected Attendees
150+
Key Organizations
40+
Expert Speakers
20+
Case Studies
2+
Days of Networking
2021 Expected Attendee Profile
Conference Agenda
Since 2012, Biologics Manufacturing Korea has witnessed huge success in bringing over 550 biologics industry pioneers from both Korea and overseas. With the mission to facilitate the development and manufacturing of high-quality biologic drugs and vaccines in Korea for the world market, Biologics Manufacturing Korea is going to continue its legacy.
Register Now!
2021 Speakers
BG Rhee SCM Lifesciences
CEOSCM LifesciencesKorea
Antonio Lee MEDIPOST America Inc.
CEO & Managing DirectorMEDIPOST America Inc.USA
George Siu Samsung Biologics
Quality Transformation LeadSamsung BiologicsKorea George is a Quality Digital Transformation Lead at Samsung Biologics, overseeing digital transformation plans and activities. Prior to joining Samsung Biologics, George held positions in Quality Control and Quality Assurance to implement and manage electronic quality systems.
Jonggu Kim GSK Global
Senior External Quality ManagerGSK GlobalKorea
Nikolai Petrovsky Vaxine Pvt. Ltd.
Chairman and Research DirectorVaxine Pvt. Ltd.AustraliaNikolai is a Professor of Medicine in the College of Medicine and Public Health at Flinders University and the founder of Vaxine Pvt. Ltd, an Adelaide-based biotechnology company. His research interests including vaccines, adjuvants, and immuno-informatics. He has been principal investigator on multiple large grants from the U.S. National Institutes of Health and has won prestigious awards including the 2010 Ernst & Young Entrepreneur of the Year Award and the 2013 Asian Executive of the Year Award. Last year, he took the first human drug developed by artificial intelligence into human influenza vaccine trials. His current focus is on the development of a vaccine against COVID-19 infection.
Andrew Wong Walvax
Vice PresidentWalvaxChina
Alois Jungbauer University of Natural Resources and Life Sciences
Head of Institute of Bioprocess Science and Engineering Department of BiotechnologyUniversity of Natural Resources and Life SciencesAustriaProfessor Alois Jungbauer received his Ph.D. in Food Technology and Biotechnology from BOKU. He serves as a professor at the Department of Biotechnology at BOKU. He teaches Protein Technology and Downstream Processing and Bioprocess Engineering and is study director of the Ph.D. program Bioprocess Engineering. He also acts as area head of Bioprocessing Engineering and Deputy Director of Research in the Austrian Centre of Industrial Biotechnology.
He is currently working in the field of bioprocess engineering of proteins, plasmids, and viruses. He has published 340 papers on recombinant protein production, bioseparation, and advanced materials for bioprocess engineering, 17 patents, and 12 book contributions, and recently a monograph entitled “Protein Chromatography, Process Development, and Scale-Up”. He is the executive editor of the Biotechnology Journal. He acts also as the vice president of research of the European Society of Biochemical Engineering Science.
Jeonghoon Han Eutilex
Vice PresidentEutilexKorea
BONGHEE LEE nSage/nGene Therapeutics
CEOnSage/nGene TherapeuticsKorea
Shubhadeep Sinha Hetero Labs Limited
Senior Vice- President & Head, Clinical Development & Medical AffairsHetero Labs LimitedIndiaDr. Shubhadeep Sinha is a senior pharmaceutical physician with over 17 years of experience in Global Clinical Development, Pharmacovigilance, Medical Affairs in Pharmaceuticals & CROs. He is currently the Vice-President and Head-global clinical, medical, and pharmacovigilance operations at Hetero group of pharmaceuticals. He is highly experienced in setting up, expanding, and operating teams in clinical development, global pharmacovigilance, medical affairs in Pharmaceuticals including Dr. Reddy’s, Hetero, Glenmark, Organon & CROs including Vimta Labs, Alquest LLC. He has also managed end-to-end clinical development of multiple biosimilars including Darbepoetin, Rituximab, Bevacizumab, Adalimumab, and currently ongoing Trastuzumab and a few others at Hetero including domestic and international development & registration.
Swapan K Jana Serum Institute of India
Director of R&D & ManufacturingSerum Institute of IndiaIndia
Udaykumar Kolkundkar Stempeutics Research Pvt. Ltd.
VP Technical OperationsStempeutics Research Pvt. Ltd. India
Dinesh Khokal Amgen
Director, External Affairs, Quality AdministrationAmgenSingapore Dinesh is currently responsible for Amgen’s outward-facing efforts in Japan Asia Pacific and Intercontinental Latin America. He collaborates effectively with industry peers and regulators to engage, understand, translate and deliver impact in the evolving external GxP landscape.
Prior to Amgen, Dinesh held the role of Director of Therapeutic Products Branch at the Singapore Medicine Regulatory Agency, Health Sciences Authority (HSA). During his 10 years tenure in HSA, Dinesh held many different roles including Senior GMP Inspector. He has also played several key roles in multiagency consortiums and World Health Organization initiatives working towards capability building, shaping the regulatory landscape, regulatory harmonization, and mutual reliance.
Prior to the roles in the regulatory agency, Dinesh held many positions in Biopharmaceutical and Medical Device industries as well as in Academia for over 20 years.
Dinesh received his Ph.D. in Cell and Molecular Biology from the National University of Singapore. He is an American Society for Quality Certified Quality Auditor and Biomedical Auditor. He has also earned certifications in Clinical Trials Management and Healthcare Policy and Governance. Dinesh is the immediate past President of the PDA Singapore Chapter and he is currently on the PDA Regulatory Affairs and Quality Advisory Board (RAQAB).
Xuezhi Bi Bioprocessing Technology Institute (BTI), A*STAR
Senior Scientist, Head of Proteomics, Analytical Science & TechnologiesBioprocessing Technology Institute (BTI), A*STARSingapore Dr. Bi XueZhi obtained his Ph.D. from Wuhan University (2000), China, followed by postdoctoral training at the International Rice Research Institute and National University of Singapore. He joined A*STAR as a research scientist and mass spectrometry facility manager in 2009, where he contributed to chemical proteomics for chemical probe/drug target identification, protein PTM, and interacting partners characterization.
Later, he was appointed as the head of the proteomics group at Bioprocessing Technology Institute, focusing on mass spectrometry-based biotherapeutics product quality attribute characterization. His work also involves proteomic profiling of upstream and downstream CHO culture processes, working closely with biotechnology and biopharmaceutical companies.
All his research subjects are related to protein and proteomics, ranging from rice, dust mites, fungus, virus, tears, sweat, cancer cell lines and tissue, embryonic stem cells, platypus venom to CHO cell-produced biotherapeutics. With many research collaborations with faculty members from signature programs such as Cancer & Stem Cell Biology, and Cardiovascular & Metabolic Disorders, he joined the faculty as an Adjunct Associate Professor, Office of Research at Duke-NUS in 2019 to share his proteomics expertise.
Sandy Qlintang PT Kalbe
DirectorPT KalbeIndonesia1. Member of Consortium of tissue engineering and stem cells, Ministry of Health (2014 – present)
2. REJASELINDO (Association of Indonesia Tissue Engineering and Cell Therapy) as Collaboration Division in 2016 – 2019
3. REJASELINDO (Association of Indonesia Tissue Engineering and Cell Therapy) as a General Secretary in 2020 - present
4. Board Member of ASPI (Asosiasi Sel Punca Indonesia) in 2020 – present
Dongil Geum Hanmi Pharmaceutical
CDMO Business Principal CoordinatorHanmi PharmaceuticalKorea
Cleo Kontoravdi Imperial College London
Associate ProfessorImperial College LondonUK
Zoltán Kis Imperial College London
Research AssociateImperial College LondonUK
Dr. Ming Ni Plasmid Virus R&D Department
Technical ManagerPlasmid Virus R&D DepartmentGenScript ProBioDr. Ming Ni received his doctoral degree from the University of Washington. He joined GenScript in January 2020 and has been responsible for technical support of the plasmid DNA platform. He led the plasmid DNA project to improve the yield and optimize purification steps. Before he joined GenScript, he was a full professor and department head of the Biomedical Engineering Department at Yachay Tech University. With over 50 peer-reviewed articles, 1600 citations, and 4 US patents, he is one of the most prolific scientists at GenScript.
Sushant Sahastrabuddhe Enteric Fever and Chikungunya, IVI
DirectorEnteric Fever and Chikungunya, IVIKorea
Dr. Li Chen GenScript ProBio
Associate Director of Biologics DiscoveryGenScript ProBioBS of Bioinformatics from the Zhejiang University of China; Ph.D. training in immunology from University of Massachusetts Medical School. After joining GenScript, Dr. Chen is in charge of the antibody-drug discovery services and has more than 10 years of experience in immunology, antibody-drug discovery, and engineering, managing over 300 antibody-drug discovery/engineering projects.
Madhu Raghunathan Thermo Fisher Scientific
Director of Global Product ManagementThermo Fisher ScientificMadhu Raghunathan is Director of Product Management at Thermo Fisher Scientific. In his current role, he is responsible for developing the technology innovation roadmap and commercializing new service offerings for the Pharma Services Group. Previously, he held strategic and operational leadership roles across Product Management, Market Development, and Strategic Marketing for a portfolio of biomanufacturing tools at a globally recognized Life Sciences company. Prior to joining the biomanufacturing industry ten years ago, he developed industrial control systems and commercialized new technology innovations for medical devices and lighting systems.
Dr. Paul Güntzel Dr. Paul Lohmann
Product ManageDr. Paul LohmannGermany
Zhiwei Song A*STAR
Principal Scientist, Bioprocessing Technology Institute A*STARSingapore
Dr Ignatius Gyepi-Garbrah Pall Biotech
Global Product ManagerPall BiotechKoreaDr. Ignatius Gyepi-Garbrah is the Global Product Manager for Single-Use Technologies at Pall Biotech. He has over 20 years of experience in downstream bioprocessing technologies and has presented regularly at international conferences, seminars, and customer locations. He has held several marketing roles in product portfolio management, market development, and business development.
He has worked at companies including MerckMillipore, Bio-Rad, and Novo Nordisk Pharmatech. Ignatius holds a Ph.D. in Biochemistry from the University of Bath. In his free time, Ignatius is an avid rugby and American football fan in his free time and enjoys practicing Wing Chun martial arts.
Kwangjun (KJ) Yoon CHA Biotech
Managing Director CHA BiotechKoreaKwangjun (KJ) Yoon is Managing Director of the Bio GMP department at CHA Biotech responsible for Cell & Gene Therapy CDMO.
Highly motivated, creative, and goal-oriented process manager and project manager over nineteen (19) years of experience in the Pharmaceutical Industry from Janssen Vaccine, Samsung Biologics, SK Chemical, and Cha Biotech in Korea. Effective working based on knowledge of three areas of process development, manufacturing and engineering.
Ross O Youngs Biosortia Pharmaceuticals
Founder and CEOBiosortia PharmaceuticalsUSARoss has spent over 30 years inventing products, technologies and processes for a variety of industries, and holds over 75 patents worldwide. He is driven to innovate by a focus on what is better, faster and less expensive. Ross’ recent major innovations include an R&D 100 Award for collaboration on biopolymer technologies. In 2009, Biosortia was awarded a $6 million ARPA-E (U.S. Dept. of Energy R&D) grant for its algal harvesting technology, which helped lead to the development of Biosortia’s drug discovery platform.
Sung Ho Hahm Rophibio
CEORophibioKorea
Wei Zhang A*STAR, Singapore
Research Scientist III & DSP Team HeadA*STAR, Singapore Singapore Currently, Dr. Zhang Wei is Staff Scientist and heading the Downstream Processing Group (DSP) in Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR) in Singapore. DSP team in BTI focuses on purification process development and product characterization for the production of a variety of biotherapeutics, including monoclonal antibodies, bispecific antibodies, vaccines, viral vectors, recombinant proteins, etc. Her team actively collaborates with many biopharmaceutical companies and bioprocessing solution providers worldwide, including both leading industrial players and local SMEs. Before that, Dr. Zhang Wei worked in Codexis Laboratory Singapore as Staff Scientist and Technical Lead, where she led a multidisciplinary research team to generate new industrial biocatalysts using directed protein evolution tools for a number of top pharmaceutical companies.
2021 Sponsors
Gold Sponsor
Silver Sponsor
Associate Sponsor
Technology Showcase Sponsor
Exhibitor
Advertiser
Supported By:
Become a Sponsor!
Position your products & services in front of senior decision-makers from both the global and Korean biopharmaceutical industry at the Biologics Manufacturing Korea 2021. You get exclusive one-to-one access to key stakeholders to present your expertise through a variety of available thought leadership, branding and exhibitor packages.
Get in touch with us about your needs today!
Market Intelligence
An update in Korean Biopharmaceutical Facilities
A closer look at Korean & International CMOs
English 
简体中文 
日本語 
한국어 
繁體中文